China Approves AstraZeneca's Tagrisso (Osimertinib) With The Addition Of Pemetrexed And Platinum-based Chemotherapy For The First-Line Treatment Of Locally Advanced Or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
China Approves AstraZeneca's Tagrisso (Osimertinib) With The Addition Of Pemetrexed And Platinum-based Chemotherapy For The First-Line Treatment Of Locally Advanced Or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.